Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
295.65 CHF | -0.72% |
|
+2.28% | +15.69% |
Feb. 13 | Roche: the stock stands out after an upgrade by UBS | CF |
Feb. 12 | Roche Wins US Approval for Spinal Muscular Atrophy Treatment in Tablet Form | MT |
P/E ratio (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Yield (Y) | Capi.($) | ||
---|---|---|---|---|---|---|---|---|---|
15.77x | 6.02x | 0.19x | 3.84x | 9.51x | 10.87x | 3.34% | 264B | ||
70.83x | 46.8x | 0.63x | 17.9x | 50.03x | 56.86x | 0.6% | 785B | ||
22.71x | 5.31x | -0.46x | 4.39x | 12.82x | 14.46x | 3.03% | 379B | ||
20.67x | 12.21x | 0.98x | 7.29x | 14.26x | 15.66x | 2.41% | 352B | ||
73.14x | 47.26x | -26.52x | 7.15x | 16.7x | 17.17x | 3.22% | 342B | ||
28.14x | 5.63x | 0.7x | 4.78x | 15.09x | 14.96x | 2.07% | 233B | ||
12.05x | 4.55x | 0x | 3.69x | 8.86x | 10.01x | 3.64% | 214B | ||
16.77x | 4.89x | 1.88x | 4.23x | 10.2x | 11.09x | 3.54% | 214B | ||
32.52x | 24.55x | -1.21x | 6.3x | 11.06x | 14.12x | 3.04% | 160B | ||
15.06x | 1.63x | 0.04x | 3.23x | 8.14x | 9.89x | 6.5% | 145B | ||
17.91x | 1.74x | 0.49x | 3.21x | 10.57x | 11.57x | 3.67% | 137B | ||
1044.15x | 6.95x | -10.68x | 5.29x | 14.14x | 18.19x | 2.89% | 132B | ||
12.61x | 5.56x | -0.06x | 3.17x | 8.32x | 8.64x | 4.39% | 114B | ||
30.46x | 6.4x | 1.49x | 9.61x | 19.28x | 20.55x | 1.24% | 78.06B | ||
17.04x | 4x | -0.56x | 2.34x | 7.2x | 8.1x | 4.17% | 73.92B | ||
29.54x | 4.02x | 1.41x | 3.38x | 18.46x | 21.77x | 1.61% | 45.92B | ||
23.89x | 2.11x | 0.53x | 3.85x | 15.48x | 17.19x | 1.58% | 44.42B | ||
51.44x | 0.92x | -4.39x | 2.35x | 9.6x | 30.82x | 4.69% | 43.35B | ||
47.3x | 6.29x | 1.22x | 9.59x | 37.68x | 40x | 0.52% | 38.92B | ||
Average | 83.26x | 10.36x | -1.81x | 5.56x | 15.65x | 18.52x | percentage-no-prefix | 199.68B | |
Weighted average by Cap. | 71.86x | 18.83x | -2.45x | 7.71x | 20.46x | 23.16x | percentage-no-prefix |
- Stock Market
- Equities
- ROG Stock
- Sector Roche Holding AG
- Sector valuations